Compare AMSS & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMSS | BCTX |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.6M | 31.1M |
| IPO Year | 2026 | 2025 |
| Metric | AMSS | BCTX |
|---|---|---|
| Price | $0.72 | $4.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | 74.7K | ★ 249.2K |
| Earning Date | N/A | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $380.95 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.60 | $2.60 |
| 52 Week High | $2.44 | $14.68 |
| Indicator | AMSS | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 34.47 | 61.99 |
| Support Level | $0.60 | $4.10 |
| Resistance Level | $1.35 | $4.38 |
| Average True Range (ATR) | 0.05 | 0.20 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 27.92 | 71.52 |
Amass Brands Inc is building a diversified premium beverage platform at the intersection of craft, wellness, and functionality. The company operates in the beverage industry, offering a portfolio that includes spirits, wine, and non-alcoholic products. The company distributes its brands in the United States through wholesale, on-premise, and direct-to-consumer channels. The company has two segments: Wine and Spirits. The majority of the company's revenue is derived from the Wine segment, which offers a portfolio of premium imported and domestic wine brands. Geographically, it operates predominantly in the USA.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.